<?xml version="1.0" encoding="UTF-8"?>
<p id="Par7">Molecular docking and other computer-related methods are efficient tools broadly used to understand the molecular aspects of protein–ligand interactions during drug discovery against many of previous emerging and fatal diseases including SARS coronavirus (Kitchen et al. 
 <xref ref-type="bibr" rid="CR17">2004</xref>; Lengauer and Rarey 
 <xref ref-type="bibr" rid="CR19">1996</xref>). In this study, virtual screening of several FDA-approved/fast-tracked drugs was performed against the SARS-CoV-2 ACE2 host receptor (PDB code = 6M0J), the SARS-CoV-2 3CL protease (PDB code = 1Q2W) and its four active sites, to find the most predicated drug–ligand interactions. The presented parameters include the docking scores, ligand binding efficiency and hydrogen bonding interactions. The top ten ranked compounds were selected and are presented in Tables 
 <xref rid="Tab1" ref-type="table">1</xref>, 
 <xref rid="Tab2" ref-type="table">2</xref>, 
 <xref rid="Tab3" ref-type="table">3</xref>, 
 <xref rid="Tab4" ref-type="table">4</xref>, 
 <xref rid="Tab5" ref-type="table">5</xref> and 
 <xref rid="Tab6" ref-type="table">6</xref> and Figs. 
 <xref rid="Fig1" ref-type="fig">1</xref>, 
 <xref rid="Fig2" ref-type="fig">2</xref>, 
 <xref rid="Fig3" ref-type="fig">3</xref>, 
 <xref rid="Fig4" ref-type="fig">4</xref> and 
 <xref rid="Fig5" ref-type="fig">5</xref>. These ten drugs include four antivirals (
 <italic>favipiravir, ribavirin, brincidofovir, and galidesivir</italic>), four antimalarial (
 <italic>chloroquine, mefloquine, primaquine, and tafenoquine</italic>) and two antimicrobial agents (
 <italic>doxycycline and atovaquone</italic>). Whether we docked against the ACE2 receptor (PDB code = 6M0J), the SARS-CoV-2 3CL protease (PDB code = 1Q2W) or the four main active sites within the SARS-CoV-2 3CL protease, the docking scores of)
 <italic>brincidofovir</italic> or BCV) were shown to be the top hit (ranked #1) compared to the other nine drugs. The docking scores for the BCV were − 10.83, − 8.30 and − 9.02 toward the SARS-CoV-2 3CL protease active site 1 (PDB code = 1Q2W), the SARS-CoV-2 3CL whole protease (PDB code = 1Q2W) (Tables 
 <xref rid="Tab1" ref-type="table">1</xref> and 
 <xref rid="Tab2" ref-type="table">2</xref> and Figs. 
 <xref rid="Fig1" ref-type="fig">1</xref>, 
 <xref rid="Fig2" ref-type="fig">2</xref>) and the ACE2 receptor (PDB code = 6M0J) (Tables 
 <xref rid="Tab3" ref-type="table">3</xref> and 
 <xref rid="Tab4" ref-type="table">4</xref> and Figs. 
 <xref rid="Fig3" ref-type="fig">3</xref> and 
 <xref rid="Fig4" ref-type="fig">4</xref>), respectively. The antimalarial drug 
 <italic>tafenoquine</italic> comes second in the rank where it scored − 8.15 and − 7.76 with the AC2 receptor and the SARS-CoV-2 3CL protease active site 1, respectively (Tables 
 <xref rid="Tab2" ref-type="table">2</xref> and 
 <xref rid="Tab4" ref-type="table">4</xref>). 
</p>
